This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Surmodics (SRDX) Gets FDA's Formal Feedback About SurVeil DCB
by Zacks Equity Research
Surmodics' (SRDX) receipt of the FDA's positive formal feedback regarding its PMA application for the SurVeil DCB looks promising.
SurModics (SRDX) Moves 5.4% Higher: Will This Strength Last?
by Zacks Equity Research
SurModics (SRDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
SurModics (SRDX) Down 37.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Surmodics (SRDX) Q1 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust Medical Device revenues.
SurModics (SRDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 21.88% and 3.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
High Tide Inc. (HITI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
High Tide Inc. (HITI) delivered earnings and revenue surprises of -20% and 7.26%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to Decline
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott (ABT) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 14.44% and 6.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
SurModics (SRDX) Surges 6.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
SurModics (SRDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Surmodics (SRDX) Stock Skids 32% on Negative Regulatory Update
by Zacks Equity Research
Surmodics' (SRDX) SurVeil drug-coated balloon candidate receives additional data requests from the FDA.
3 Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Surmodics (SRDX) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust Medical Device revenues.
SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 31.58% and 4.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ICU Medical (ICUI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 24.11% and 6.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 164.71% and 9.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Surmodics (SRDX) Beats on Q3 Earnings, Revises FY22 View
by Zacks Equity Research
Product sales primarily drive Surmodics' (SRDX) third-quarter top-line growth. However, the company expects softer demand for its products and services in the second half of 2022.
SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 12.82% and 2.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
Haemonetics (HAE) Up 28.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View
by Zacks Equity Research
Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.